- In March 2023, LifeCell International, an Indian company, introduced the 'PrepaCyte-CB' cord blood processing technology, ensuring the growing stem cell yield
- In October 2021, Americord Registry LLC, a U.S.-based biotechnology firm, opened a new research and development (R&D) and cell processing laboratory in New York City. The facility aims to innovate regenerative medicine solutions, advancing stem cell applications for treating cancers, neurological disorders, and autoimmune conditions
- In September 2021, CBR Systems, Inc., a U.S.-based newborn stem cell bank, announced that over 10,000 families had joined the Newborn Possibilities Program (NPP). This initiative focuses on preserving umbilical cord blood for children diagnosed with serious conditions or at risk of pediatric developmental disabilities, while also providing healthcare providers with training to identify potential candidates for stem cell treatments
- In October 2020, American Cryostem Corp, a U.S.-based biotechnology company, partnered with BioTherapeutic Labs (BTL) Corp., an umbilical cord tissue manufacturing company. The collaboration focuses on marketing CRYO's autologous mesenchymal stem cell products and advancing R&D protocols using BTL's umbilical cord-based product lines, expanding market reach and demand for cord blood services
- In August 2020, CBR Systems, Inc., a U.S.-based private newborn stem cell bank, collaborated with NantKwest Inc., a clinical-stage immunotherapy company, to develop a COVID-19 treatment using newborn stem cells. CBR provided umbilical cord tissue-derived mesenchymal stem cells (MSCs) to NantKwest for expansion through its proprietary bioreactor system, highlighting the growing demand for cord blood applications
Frequently Asked Questions
The market is segmented based on Segmentation, By Storage Service (Public Cord Blood Banks, Private Cord Blood Banks, and Hybrid Cord Blood Banks), Therapeutics (Cancer, Diabetes, Blood Diseases, Immune Disorders, Metabolic Disorders, and Other Diseases), Application (Transplant Medicine and Regenerative Medicine) – Industry Trends and Forecast to 2032
.
The Global Stem Cell Umbilical Cord Blood Market size was valued at USD 6.20 USD Billion in 2024.
The Global Stem Cell Umbilical Cord Blood Market is projected to grow at a CAGR of 12.04% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
